There are a lot of kinomics technologies out there. As a cancer researcher, I have tried quite a few of them. However, I have been most pleased with the PamStation technology from PamGene International.

As opposed to other systems, the PamStation actually measures kinase enzymatic activity because it detects new phosphorylation events produced by the active kinases within a biological specimen. Importantly, because it measures enzyme function, it is possible to incorporate enzyme inhibitors into the test samples. This ability to do “ex vivo” profiling is very unique. Ex vivo testing provides an additional level of interrogation of an otherwise “static” sample. For instance, one can take a tumor biopsy specimen from a patient and determine the basal kinomic profile of that tumor. However, only with the PamStation will you be able to see how the kinomic profile is modified when the specimen is treated with a kinase inhibitor(s). In other words, you can subject your specimen to a kinase inhibitor “challenge” to see if there is a level of resistance or sensitivity inherent to the specimen.


Based on these clear advantages, we decided to invest in the PamStation platform and have developed the Kinome Core Facility. Since 2010, we have been operating a fee-for-service facility that has enabled numerous investigators to expand their research and identify new areas of study.